- Written communication by the subject company relating to a third party tender offer (SC14D9C)

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

SCHEDULE 14D-9

(Rule 14d-101)

 

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

 

---

 

ALLOS THERAPEUTICS, INC.

(Name of Subject Company)

 

ALLOS THERAPEUTICS, INC.

(Name of Persons Filing Statement)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

019777101

(CUSIP Number of Class of Securities)

 

---

 

Paul Berns

Chief Executive Officer

11080 CirclePoint Road, Suite 200

Westminster, CO 80020

[phone]

(Name, address and telephone number of persons authorized to receive

notices and communications on behalf of the persons filing statement)

 

With copies to:

Peter F. Kerman

Joshua M. Dubofsky

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94025-3656

[phone]

 

x                   Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by Allos Therapeutics, Inc. on April 6, 2012 (including all exhibits attached thereto) is incorporated herein by reference.

 

 

 

---